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Regulatory and functional interaction of vasoactive factors
in the kidney and extracellular pH. A growing body of
evidence suggests that vasoactive factors produced in the
kidney such as nitric oxide, endothelins, angiotensin, and
prostaglandins participate actively in the regulation of acid-
base homeostasis under physiologic conditions. In addition,
recent reports indicate that alterations in the systemic acid-
base status may also influence the generation of vasoactive
cytokines in the kidney, which in turn may mediate the re-
nal effector processes that tend to restore normality un-
der such conditions. Metabolic acidosis, which so frequently
accompanies many forms of chronic renal failure (CRF), may
contribute to down-regulation of intrarenal nitric oxide pro-
duction that characterizes CRF. Reduced extracellular pH
inhibits inducible nitric oxide production in mesangial cells
by altering the reduced form of nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidation, an important post-
translational mechanism in the inducible nitric oxide synthase
(iNOS) activation. The underlying defects resulting in the
uncoupling of NADPH oxidation in acidemic microenviron-
ment are discussed. Acidosis stimulates renal production of
endothelins, which mediate proximal tubular acidification by
enhancing sodium-hydrogen exchanger-3 (NHE-3) activity. Re-
nal endothelins mediate enhanced urinary acid excretion fol-
lowing dietary acid ingestion, an effect that is effectively
blocked by endothelin receptor blockers. Reduced extracellu-
lar pH stimulates endothelin secretion from renal microvas-
cular endothelial cells, which may promote enhanced acid
excretion from the distal tubule under conditions of acidosis.
These phenomena as well as the role of angiotensin and renal
prostaglandins in mediating renal acidification in normal and
acidotic conditions are discussed in this review, which describe
the regulatory interaction between extracellular pH and renal
vasoactive factors.
Recent literature has established the significance of va-
soactive factors produced in the kidney in regulation of
normal renal function as well as in the development and
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progression of renal disease through hemodynamic and
nonhemodynamic effects. Such factors include nitric ox-
ide, endothelins (ETs), prostaglandins, and angiotensin.
Several experimental and clinical studies have supported
the concept that activation of renin-angiotensin axis and
down-regulation of L-arginine-nitric oxide pathway ac-
celerate the renal failure caused by different etiologies,
specifically diabetes [1, 2]. Acidosis, which is an important
and integral feature of chronic renal failure (CRF), has
been shown to influence the renal production of ETs and
nitric oxide, an effect that can potentially contribute to
the course of renal failure. In addition, alterations in the
production of vasoactive factors in the kidney may consti-
tute important effector mechanisms, which mediate renal
responses to the systemic acid-base disturbances. More-
over, in systemic conditions associated with acidosis such
as septicemia and diabetic ketoacidosis, vasoactive fac-
tors mediate many clinical consequences of the primary
disorder. This review attempts to provide an overview of
the current understanding of the physiologic role of va-
soactive factors produced by the kidney in systemic pH
regulation and alterations in their production in response
to systemic acid-base disturbances.
NITRIC OXIDE
Immediately following the identification of
endothelial-derived relaxing factor (EDRF) as ni-
tric oxide, the scientific literature was flooded with
reports supporting the role of nitric oxide as a paracrine
mediator of a variety of physiologic and pathologic ef-
fects in various organs systems. Specifically in the kidney,
studies indicated that nitric oxide plays an important
role not only in the control of renal hemodynamics,
tubuloglomerular feedback, and glomerular filtration,
but also in the regulation of tubular transport processes
in various segments. Three isoforms of the enzyme,
nitric oxide synthase (NOS) mediate the conversion
of L-arginine to L-citrulline, which is the sole pathway
for the generation of endogenous nitric oxide. All
the three isoforms [neuronal NOS (nNOS or NOS I),
inducible NOS (iNOS or NOS II) and endothelial NOS
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(eNOS or NOS III)] are expressed differentially in
various segments of nephron. nNOS and eNOS are
traditionally considered as constitutively expressed and
with limited tissue distribution, exhibiting intracellular
Ca++/calmodulin dependency. On the other hand, iNOS
is an inducible enzyme, expressed in all nucleated cells
and generate large bursts of nitric oxide in response
to immunologic stimuli. iNOS is generally considered
Ca++-independent although the presence of Ca++
enhances its activity. In view of the high diffusibility,
nitric oxide generated in renal microvasculature or
tubular cells can affect the function in adjacent parts of
the nephron, and thus function as a paracrine mediator.
Many experimental models of CRF and even clinical
evidence indicate that intrarenal nitric oxide production
is decreased in many forms of CRF [3] and may con-
tribute to the progression of renal failure by accelerating
glomerular and interstitial sclerosis [4]. Since metabolic
acidosis is a major consequence of renal failure, it is im-
portant to understand the effects of acid-base changes
on the nitric oxide production in the kidney. Although
the regulation of nitric oxide synthesis in various organs
and cell systems has been extensively studied, the litera-
ture on the effects of pH on nitric oxide synthesis is lim-
ited. The following paragraphs summarize the available
literature on the role of nitric oxide in the renal acidifica-
tion mechanisms under physiologic and pathophysiologic
conditions and the effects of extracellular pH (pHe) on ni-
tric oxide production with special reference to intrarenal
nitric oxide generation.
ROLE OF NITRIC OXIDE IN RENAL
ACIDIFICATION
Recently published data supports the role of nitric ox-
ide as an important regulator of acidification in the vari-
ous segments of renal tubule. The proximal tubule, under
normal conditions, is responsible for reabsorbing 70%
to 90% of the filtered bicarbonate and 50% of the fil-
tered chloride. Bicarbonate reabsorption is mediated by
H+ secretion across the apical membrane of the prox-
imal tubule and occurs by two different mechanisms.
The major fraction (60% to 70%), of H+ secretion oc-
curs by a Na+-dependent, amiloride-inhibitable process
mediated by an apical Na+/H+ antiporter or exchanger
(NHE). The remaining 30% to 40% of the H+ secretion
occurs by a Na+-independent amiloride-insensitive pro-
cess, mediated by adenosine triphosphate (ATP)-driven
H+ transport. Bicarbonate reabsorption across the ba-
solateral membrane is facilitated predominantly by an
electrogenic Na+−3HCO3− cotransporter.
Murer, Hopfer, and Kinne [5] were the first to demon-
strate that H+ secretion may be directly linked to lumi-
nal Na+, implicating Na+/H+ exchange. The first Na+/H+
antiporter was cloned by Sardet, Franchi, and Pouysse-
gur [6], which was subsequently named NHE-1. Since
then, six additional mammalian isoforms of NHE have
been cloned (NHE 2 to 7). Among the seven isoforms,
only NHEs 1 to 4 are expressed in the kidney. NHE-1
and NHE-4 are expressed exclusively on the basolateral
membrane. Practically all of the apical Na+-H+ exchange
activity of the proximal tubule is accounted by NHE-3 iso-
form, as confirmed by molecular, immunocytochemical,
and inhibitor sensitive studies [7].
The effects of nitric oxide on proximal tubular acidi-
fication mechanisms are controversial. Studies by Wang
[8] showed similar increases in the HCO3 transport with
a nitric oxide donor, S-nitroso N-acetyl-D,L, Penicil-
lamine (SNAP), as well as 8-bromocriptine guanosine
monophosphate (BrcGMP), which mediated the effects
of nitric oxide. These studies however showed that ni-
tric oxide stimulated proximal tubular Na+ and HCO3
transport through cyclic GMP (cGMP)-linked pathway
by augmenting NHE activity in the proximal tubule. The
same investigators [9] later demonstrated that in nNOS
knockout mice models the bicarbonate flux (JHCO3) was
significantly reduced compared to the wild-type and these
animals developed metabolic acidosis. Similar observa-
tions were made in the iNOS knockout mice [10]. All
of these studies indicated that endogenous nitric oxide
from iNOS and nNOS promoted HCO3 transport and
H+ secretion, while eNOS had no demonstrable effect
on modulation of proximal tubular sodium and bicar-
bonate transport. Amorena and Castro [11] first indi-
cated that nitric oxide from endothelial cells might be
involved in the regulation of acidification mechanisms in
the proximal tubule. They showed in co-culture studies of
proximal tubular and endothelial cells, that L-arginine
analog N-nitro-L-arginine methyl ester (L-NAME)
blocked and cGMP enhanced the rate of H+ flux (JH)
in proximal tubules driven by carbachol. They concluded
that the peritubular endothelium exerts control on the
proximal tubular acidification by stimulating Na+/H+ ex-
changer activity in proximal tubule and that this effect
was mediated by endothelial nitric oxide. But thus far
there is no evidence that eNOS independently affects the
acidification mechanisms in proximal tubule.
On the contrary, other studies have shown that nitric
oxide inhibited fluid reabsorption and acidification in the
proximal tubule. Using split-drop micropuncture tech-
nique, Eitle et al [12] reported that sodium nitroprusside
(SNP), a nitric oxide donor, inhibited fluid reabsorp-
tion in proximal tubule. Furthermore, a few other stud-
ies demonstrated that nitric oxide inhibited Na+/H+
exchange in proximal tubule [13]. In both freshly iso-
lated proximal tubular segments and in primary cultures
of proximal tubular cells [14], SNP caused significant in-
hibition of apical Na+/H+ exchanger, an action mediated
at least partly by cGMP. These investigators explained
the discrepancy between their findings and those in NOS
knockout studies cited earlier [10] by the following ar-
guments. First, in nNOS knockout models, lack of nNOS
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expression in the gastrointestinal tract, for instance, re-
sults in severe intestinal malformations that could lead
to alterations in electrolyte transport [15]. Furthermore,
the in vitro transport characteristics in isolated proxi-
mal tubule preparation may be modified by denervation,
since neuronal activity modulates nitric oxide production.
Additionally, L-NAME may cause a paradoxic increase
in nitric oxide production in renal cortex [16] which is
in agreement with the observations of Wang, Inglis, and
Kalb [9]. The latter study demonstrated that intravenous
infusion of L-NAME in mice as well as in in situ mi-
croperfusion of proximal tubule resulted in natriuretic
and diuretic effects. These data strongly suggest that the
effects of L-NAME on tubular transport are not only
difficult to interpret but also may represent effects that
are independent of their effects on nitric oxide produc-
tion. Furthermore, immunocytochemical and molecular
biologic studies failed to demonstrate the expression of
nNOS and iNOS in the proximal tubule.
In summary, the available evidence relating to effects
of nitric oxide in proximal tubule supports both stimula-
tion and inhibition of NHE activity. The discrepant ob-
servations may relate to differences in the nitric oxide
concentrations, a stimulatory effect seen in lower con-
centrations (in micromolar range) and inhibitory effect
in higher (millimolar) concentrations. Direct measure-
ments of nitric oxide concentrations in the kidney tubules
in vivo have yielded low concentrations (110 nmol/L) in
both early and late proximal tubules [17]. These concen-
trations are similar to those used in vivo microperfusion
studies [8] and NOS knockout studies [9, 10] cited earlier,
where a stimulatory effect of nitric oxide on fluid reab-
sorption (Jv), sodium reabsorption and NHE activity was
demonstrated. Thus, under physiologic conditions, nitric
oxide stimulates proximal tubular sodium reabsorption
and H+ secretion through increased NHE activity. While
nitric oxide derived from nNOS and iNOS seem to medi-
ate such effects, there is no evidence that eNOS-derived
nitric oxide plays any independent role in proximal tubu-
lar acidification and sodium reabsorption.
Studies by Ruiz et al [18] have shown that ni-
tric oxide might modulate the activity of Na+-3HCO3
cotransporter in the rabbit proximal tubule. Carbachol,
a cholinergic agent, increases nitric oxide production in
proximal tubules. They showed that L-NAME, a NOS
inhibitor, prevented the augmentation of the activity of
Na+-3HCO−3 cotransporter that is normally seen with car-
bachol. Nitric oxide thus plays a role in the renal acidifi-
cation mechanisms in the proximal tubule by modulating
the activity of Na+-3HCO−3 cotransporter.
In conclusion, despite conflicting data, majority of ev-
idence points out that nitric oxide stimulated Na+ and
HCO3− reabsorption by stimulating Na+/H+ exchanger
and through augmenting basolateral electrogenic Na+-
3HCO3− cotransporter. Thus, nitric oxide participates in
the proximal tubular acidification mechanisms by at least
two distinct mechanisms. Currently, there are no data im-
plicating nitric oxide modulation of HCO3− reabsorption
through electrogenic H+ secretion.
In the medullary thick ascending limb of loop of Henle
(mTALH), nitric oxide inhibited net Cl− and HCO3−
absorption by modulating the activity of the Na+-K+-
2Cl− cotransporter and Na+/H+ exchanger [19]. Ortiz,
Hong, and Garvin demonstrated that nitric oxide inhib-
ited Na+/H+ exchanger activity at both apical and ba-
solateral sides of the mTALH. By using a nitric oxide
donor spermine NONOate (Cayma Chemical Ann Ar-
bor, MI, USA), these investigators showed that nitric
oxide decreased the intracellular pH. Furthermore, they
measured the recovery from acid loading by measuring
JH and found that spermine NONOate decreased JH in
mTALH. The relative contributions of apical and baso-
lateral Na+/H+ exchanger activity were determined by
examining the effects of spermine NONOate on JH in
mTALH in the presence of dimethyl amiloride in the bath
or lumen. The data confirmed that nitric oxide inhibited
both apical and basolateral Na+/H+ exchanger activity
in mTALH. Consequently, nitric oxide may play an im-
portant role in bicarbonate reabsorption and thereby af-
fecting renal tubular acidification in mTALH [20]. At the
present time, there are no reports of nitric oxide modulat-
ing H+ secretion in the distal tubule. In collecting duct,
nitric oxide inhibits H+ ATPase activity in the interca-
lated cells of the collecting duct [21].
Effects of pHe on the nitric oxide production in the kidney
Clinical conditions in which the systemic and tissue
acid-base status is altered impact significantly on cel-
lular function. These functional changes may be medi-
ated at least in part by alterations in local nitric oxide
synthesis. The resultant changes in nitric oxide could
be due to changes in expression or activity of NOS or
due to decreased nitric oxide metabolites due to forma-
tion of reactive nitrogen species such as peroxynitrite.
For example, acidosis stimulated nitric oxide synthesis
in rat lung as measured by exhaled nitric oxide concen-
tration [22]. On the other hand, studies by Bellocq et al
[23] demonstrated that macrophages exposed to acidic
pH (7.0), simulating the microenvironment of inflam-
mation, showed increased iNOS activity through activa-
tion of nuclear factor-kappaB (NF-jB). Similarly, Unno,
Hodin, and Fink [24] demonstrated stimulation of NOS
activity in the presence of acidemia when the investiga-
tors exposed intestinal smooth muscle cells to decrease
pHe. However, in these experiments, nitric oxide genera-
tion was decreased due to the formation of peroxynitrite
and hydroxyl radical formation, while the expression of
iNOS protein itself was not affected. Reduced pHe (7.0)
decreased nitric oxide generation in inflammatory cells
despite an increase in iNOS activity [25].
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Cellular uptake of calcium has also been implicated
in mediating the pH effects on NOS activity. Activity of
eNOS is inhibited at reduced pHe while it is increased
with elevated pHe. For instance, intracellular acidosis
(pH 6.7) inhibited [26] and alkalosis stimulated eNOS
activity in pulmonary endothelial cells by stimulating
the influx of extracellular calcium flux [27]. In the lat-
ter studies, blockade of Na+/Ca2+ exchanger with 3′4′
dichlorobenzamil hydrochloride prevented the increase
in eNOS activity, suggesting that Na+/Ca2+ exchanger
regulates eNOS activity in acid-base disorders. In vascu-
lar smooth muscle, the effects of acidosis depend on the
net effect of the pH on nitric oxide synthesis and the di-
rect vasodilatory effect on the smooth muscle cells [28].
The latter may depend on the effects of pHe on intracellu-
lar calcium, probably mediated by Ca++/H+ exchanger.
Furthermore, the pH effects on vascular tone have been
clarified in the light of pH sensitive florescent studies.
It is likely that while decreased intracellular pH accounts
for the immediate responses to acidosis, it is reduced pHe
that modulates the vascular tone in the steady state of aci-
dosis [29]. In summary, the effects of pH on nitric oxide
synthesis are variable and dependent on the cell type and
NOS isoform involved and may be mediated in certain
conditions by transcellular calcium fluxes.
The effects of changes in pHe on nitric oxide genera-
tion specifically in the kidney are not well understood.
Studies in rat proximal tubules suggested that reduced
pHe prevented hypoxia mediated nitric oxide synthesis
[30]. Compared to a pH of 7.4, nitric oxide synthesis in
proximal tubules was reduced at a pH of 7.0 despite hy-
poxia. These studies indicated that acidosis protects the
proximal tubule from the deleterious effects of increased
nitric oxide production resulting from hypoxia.
I hypothesized that pHe regulates the inducible ni-
tric oxide synthesis in the kidney. Specifically, I ex-
amined nitric oxide synthesis in mesangial cells [31]
since nitric oxide derived from mesangial cells has been
shown to modulate mesangial cell proliferation and ma-
trix production [32]. My studies indicated that in murine
mesangial cells in culture reduced pHe inhibited in-
ducible nitric oxide synthesis (Fig. 1) while alkaline
pH (pHa) did not affect mesangial nitric oxide produc-
tion. The nitric oxide inhibition in acidosis was associ-
ated with decreased activity of iNOS, while iNOS gene
and protein expression was unchanged from the control
conditions. Further examination of the mechanisms un-
derlining iNOS inhibition in acidic medium indicated
that posttranslational factors such as tetrahydrobiopterin
(BH4) or substrate (L-arginine) supplementation did not
influence the nitric oxide inhibition, while the oxidation
of NADPH (reduced form of nicotinamide adenine din-
ucleotide phosphate) was significantly increased. Eval-
uation of NADP+/citrulline stoichiometry under these


































Fig. 1. Effects of extracellular pH (pHe) on nitrate and nitrite (NOx)
accumulation in murine mesangial cells. Control pH (Con) is 7.3 while
acidic and alkaline pH is 7.0 and 7.6, respectively. Abbreviations are:
T, tumor necrosis factor-a (TNF-a), L, lipopolysaccharide (LPS). ∗P <
0.001 compared to control (N = 12 in each group). Reprinted from
Prabhakar SS, Kidney Int 61:2015–2024, 2001. Permission requested.
(Fig. 2A). I concluded that acidosis inhibited iNOS ac-
tivity by altering NADPH oxidation, an important post-
translational mechanism in iNOS activation. Currently, it
is unclear whether increased oxidation of NADPH in re-
duced pHe conditions, is due to activation of NADPH
oxidase or due to the excess H+ that may shift the
NADPH → NADP+ reaction to the right. My observa-
tions indicate that the latter may be the case (Fig. 2).
Specifically, it is difficult to examine the role of NADPH
oxidase activity since most inhibitors of NADPH also in-
hibit iNOS activity. My studies also demonstrated that un-
der reduced pHe conditions, saturating concentrations of
NADPH normalized iNOS activity but not the NADPH-
iNOS coupling. Thus, it is likely that increased rate of
NADP+ formation with resultant substrate (NADPH)
depletion leads to reduced iNOS activation and uncou-
pling of NADPH oxidation.
Generation of nitric oxide from its precursor L-arginine
involves cofactors such as BH4, flavin mononucleotide
(FMN), and flavin adenine dinucleotide (FAD), which
shuttle electrons from the substrate NADPH at the en-
zyme site. This process occurs in two steps. The first
step involves a two-electron oxidation supplied by one
molecule of NADPH resulting in the formation of N-
hydroxy L-arginine. In the second step, a second oxy-
gen is supported by 0.5 molecule of NADPH leading to
the formation of nitric oxide and citrulline. Thus, dur-
ing the process of normally coupled iNOS activation, the
NADP:citrulline stoichiometry is between 1.5 and 2.0.
The iNOS activity is influenced by NADPH oxidation,
which in turn is controlled by NADP+/NADPH ratio in
the cytosol. A potential explanation for increased genera-
tion of NADP+ under reduced pH conditions may involve









0 5 10 15 20 25 30 35
Time, minutes
A
(  ) (  ) [3H citrulline pH 7.0
[3H citrulline pH 7.3(  )
NADP+pH 7.0

























Citrulline generation NADP+ production
B
Fig. 2. Effects of pHe on inducible nitric oxide synthase (iNOS)-
reduced form of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidation coupling. (A) Time course of iNOS activation
and NADP+ generation. Inhibition of iNOS activity seen with re-
duced exctracellular pH (pHe) is associated with increased rate of
NADPH oxidation with uncoupling of NADP+/citrulline stoichiome-
try. The NADP+ and citrulline generation are measured at several time
intervals using the in vitro iNOS assay in reaction mixtures incubated
at pH 7.0 and pH 7.3. As shown in the figure, excess H+ in low pHe con-
ditions drive the reaction of NADPH → NADP+ to the right. Symbols
are: () NADP+ pH 7.0; () NADP+ pH 7.3; (•) [3H] citrulline pH
7.0; (	) [3H] citrulline pH 7.3. The values shown represent the mean
of four experiments in each group. (B) Citrulline-NADP+ coupling.
Effects of NADPH supplementation. Increased NADPH → NADP+
conversion associated with reduced pH may lead to rapid depletion of
NADPH accounting for decreased iNOS activity. To verify this hypoth-
esis, NADP+ () and citrulline generation (iNOS activity) () were
measured in three sets of experiments that included (A) lysates from
murine mesangial cells (MMC) stimulated at 7.0 pH, (B) lysates from
MMC stimulated at pH 7.0 along with saturating (50 mmol/L) concen-
trations of NADPH, and (C) lysates from MMC stimulated at control
(7.3) pH. NADPH concentration in groups (A) and (C) is 10 mmol/L (N
= 6 in each group). ∗P < 0.01 vs. corresponding result in group (A). (B)
NADPH supplementation resulted in increased iNOS activity. How-
ever the uncoupling of NADPH → citrulline persisted. Reprinted from
Prabhakar SS, Kidney Int 61:2015–2024, 2001. Permission requested.
a decreased NADP+/NADPH ratio due to excess H+, re-
sulting in increased concentration of NADPH. Further-
more, the optimal pH for iNOS (7.0 to 8.0) is significantly
higher than that for NADPH oxidation (5.5 to 6.5). Thus,
uncoupling of iNOS activation and NADPH oxidation at
reduced pHe conditions is accounted for in part by the
aforementioned differences in pKa of NADPH oxidase
and iNOS enzymes.
The pH-dependent uncoupling of iNOS could also be
explained by destabilization of the iNOS homodimers un-
der reduced pHe conditions. Monomers of iNOS oxidize
NADPH, but unlike dimers, monomers cannot synthe-
size nitric oxide. Recent literature suggests that nNOS
activity is inhibited by reduced pHe, due to an increased
monomer-dimer ratio [33]. Presently it is unknown if sim-
ilar pH-dependent effects on stability of dimmers is seen
with other isoforms of NOS. The iNOS inhibition under
conditions of reduced pHe is not universal and is tissue-
and cell-specific. For instance, macrophages exhibit en-
hanced iNOS activity under these conditions and not sur-
prisingly, this effect is associated with normal NADPH
coupling [31]. These studies suggest that acidosis may im-
pair nitric oxide production in the kidney and support the
notion that acidosis may be one of the contributors to ni-
tric oxide deficiency in CRF.
Endothelins (ETs)
Endothelin (ET), first described by Yanagisawa et al
in 1988 [34], is a potent endothelial-derived vasoconstric-
tor as well as a sodium-regulating peptide. The ET sys-
tem comprises of four endothelins (ET1−4) and the re-
ceptors that mediate the biologic actions of ETs. In the
kidney, ET1 is synthesized in the endothelium of renal
vasculature (both in macrovasculature and microvascu-
lature), mesangial cells, peritubular capillaries and in the
epithelium of the proximal tubule, mTAL [35] and the col-
lecting duct, especially in inner medullary collecting duct
(IMCD) [36]. The biologic effects of ETs are mediated
by specific receptors. ETA receptors are predominantly
distributed in the vasculature of glomeruli and medulla
while ETB receptors are present in the renal tubules and
collecting ducts [37]. ET1 secretion is primarily regulated
by transcription and partly by extracellular factors such as
osmolality and humoral agents such as antidiuretic hor-
mone. ETs are not only powerful vasoconstrictors but
also mediate some nonhemodynamic renal functions [38].
Role of ETs in proximal tubular acidification mechanisms
Several lines of evidence incriminate ETs in the renal
acidification mechanisms under physiologic conditions
and in mediating renal responses initiated by metabolic
acidosis [7, 38, 39, 40]. Chronic metabolic acidosis is
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Fig. 3. Mechanisms of endothelin (ET)-mediated effects on H+ secre-
tion resulting from tissue acidosis.
usually associated with reduction of both extracellu-
lar and intracellular pH. However, chronic potassium
deficiency is associated with decreased intracellular pH
with no change in pHe. ETs, particularly ET1, modulate
the NHE-3 activity in the proximal tubule which in turn is
responsible for the regulation of proximal tubular apical
H+ secretion. ET1 increases the activity of renal corti-
cal brush border Na+-H+ antiport activity and the baso-
lateral Na+-3HCO3− transporter [41]. Recent studies by
Laghamani, Preisig, and Alpern [7] demonstrated that in
metabolic acidosis, NHE-3 activity is stimulated by ET1
working through ETB receptor. Furthermore, these in-
vestigators showed that ET1/ETB-stimulated NHE-3 ac-
tivity was due to an increase in apical NHE-3 abundance,
which resulted from an increased exocytotic insertion of
NHE-3 into the apical membrane [39]. In this study, the
authors also established that the stimulation of NHE-3
activity by decreased intracellular pH depended on ac-
tivation of Pyk2, c-Src (nonreceptor tyrosine kinases)
and increased expression of the immediate early genes,
c-Fos/cJun. Regulation of c-Fos/c-Jun may involve
mitogen-activated protein (MAP) kinase family (Fig. 3).
Role of ETs in distal tubular acidification mechanisms
ETs play an important role in renal acidification
mechanisms in nephronal segments beyond the prox-
imal tubule. For example, in the rat TALH, chronic
metabolic acidosis increased mRNA and protein expres-
sion as well as the activity of NHE-3 [42]. The primary
mechanism by which distal tubule contributes to acidifi-
cation of urine is by titration of nonbicarbonate buffers.
Reclamation of filtered bicarbonate that escapes prox-



















Fig. 4. Cell-associated endothlin (ET-1) concentrations in renal mi-
crovascular endothelial cells (RMVECs) after 12 hours of incubation
in control (pH 7.2), alkaline (pH 7.4), and acidic (pH 7.0) media. ∗P <
0.05 vs. control. Reprinted from Wesson et al, J Clin Invest 101:578–583,
1998. Permission requested.
contributing to urinary acidification. Luminal H+ secre-
tion occurs in both processes and involves Na+/H+ ex-
change, H+/K+ ATPase and H+-ATPase. In addition,
Cl−/HCO3− exchanger mediates bicarbonate secretion in
the distal tubule. Augmented distal tubular acidification
in response to dietary acid digestion is mediated by re-
duced bicarbonate secretion and increased H+ secretion.
Sustained changes in extracellular or intracellular acid-
base parameters do not necessarily precede increased
urinary acidification. Published studies evaluating the ef-
fect of ETs on distal acidification are very limited and
were performed exclusively by Wesson and Dolson [40].
They demonstrated that intra-arterial infusion of ET1 en-
hanced distal tubular acidification by increasing luminal
H+ secretion as well as by decreasing bicarbonate secre-
tion. In addition, ET1 secreted by renal microvascular
ET cells mediated increased distal tubular acidification
induced by dietary acid [43]. Furthermore, blockade of
ET1B and not ET1A receptors blocked the tubular re-
sponse of increased urinary acidification.
Effect of pHe on ETs
The influence of pHe on ET1 secretion in the kid-
ney was convincingly demonstrated by Wesson et al [43,
44]. Using human renal microvascular endothelial cells
(RMVEC), these investigators showed that pHe influ-
enced the ET1 produced by RMVEC. Acidic pH (7.0)
stimulated ET1 production compared to standard or con-
trol pH (7.2), while pHa (7.4) had no effect on basal ET1
production (Fig. 4). Thus, reduced pHe enhanced ET1
production by RMVEC, while under similar experimen-
tal conditions; ET1 secretion was unaffected in macrovas-
cular (aortic) endothelial cells. These data offer a
potential explanation by which dietary acid could
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enhance renal cortical ET1 production, which is by
increasing renal cortical acid content. The increase in re-
nal cortical acid content leads to increased ET1 levels in
the interstitial fluid, which bathes both distal tubule ep-
ithelium and renal microvasculature possibly providing
a paracrine communication between them. The authors
suggest that since ET1 increases fibronectin and colla-
gen synthesis, the increased ET1 levels resulting from a
reduced renal mass may play a role in progressive re-
nal sclerosis. The cellular microenvironment in renal fail-
ure, which includes acidosis, may affect the renal function
through effects on ET1 production.
However, as the authors acknowledged, the exact
mechanisms by which lowered pHe stimulated the ET1
production was not clear from these studies [43, 44].
Specifically, they did not exclude the effect of lower bicar-
bonate on ET1 production independent of effects from
lower pHe. Furthermore, kinases are known to modulate
ET1 production. For instance, protein kinase C modulates
angiotensin II–induced ET1 synthesis [45] and tyrosine
kinase mediates insulin induced ET1 synthesis [46]. Cur-
rently, it is unknown if kinases play any role in mediating
the pH effects on ET1 production. The observation that
decreased pHe in the studies of Wesson et al stimulated
ET1 synthesis in microvascular but not in macrovascular
endothelial cells indicates differential sensitivity of ET1
to pHe in different cell types. These differences in pH
sensitivity may relate to the magnitude of basal ET1 se-
cretion, and differences in the microenvironment that the
endothelial cells are bathed in. Specifically, the basal pH
of the medium that bathes the renal microvasculature is
more acidic than that bathing the aortic endothelium [44].
Recent studies [47] indicate that chronic metabolic acido-
sis enhances the expression of pre-pro ET1 in the kidney
cortex, proximal tubule, and glomeruli and the increased
expression correlates with the decrease in blood HCO3.
In summary, ET1 plays an important role in mediat-
ing the renal responses to systemic acid-base challenges
and provides a mechanism for adaptive renal actions un-
der physiologic and pathologic states. Changes in pHe
and acid-base status result in alterations in renal ETs
that account for titration of renal acidification mecha-
nisms both at proximal and distal tubular level. Further-
more, the up-regulation of ET1 under acidic microenvi-
ronment may provide yet another mechanism for fibrosis
and sclerosis, events that account for progressive renal
functional deterioration that occurs in most forms of CRF
[48].
ANGIOTENSIN
The kidney is both an important source of several com-
ponents of the renin-angiotensin system as well as a target
organ for their actions. Angiotensinogen is converted to
angiotensin I by renin, and mRNA for both angiotensin
and renin are found in juxtaglomerular cells and re-
nal tubular cells. Angiotensin-converting enzyme (ACE),
which cleaves angiotensin I to angiotensin II, is found
principally in the lung but also in other tissues including
the kidney. The principal effector of renin-angiotensin
axis is angiotensin II, the biological actions of which are
mediated through activation of at least two receptor sub-
types, AT1 and AT2. Most angiotensin II effects are be-
lieved to be mediated by AT1 receptors while AT2 re-
ceptors are believed to be expressed only in fetal life al-
though evidence is emerging in the recent literature for
not only the expression but also for a functional role of
AT2 receptors in adult life. In addition to being a cir-
culating hormone with strong vasoconstrictive effects in
systemic and glomerular hemodynamics, angiotensin II
has important paracrine effects on cell proliferation and
tubular transport.
Role of angiotensin in renal acidification
Angiotensin II participates in the renal acidifica-
tion mechanisms under normal conditions through sev-
eral mechanisms. In the proximal tubule, angiotensin
II stimulates Na-HCO3 reabsorption by increasing the
apical Na+/H+ antiporter activity (both through cAMP-
dependent and cAMP-independent mechanisms) and
also by stimulating the basolateral Na+-3HCO3 cotrans-
porter activity. Using in vivo microperfusion of rat prox-
imal convoluted tubule, Liu and Cogan [49] have first
shown that angiotensin II increases proximal tubular bi-
carbonate reabsorption by a G1 protein–mediated inhi-
bition of intracellular cAMP. However, the same group
as well as others later had shown that protein kinase C
activation without changes in intracellular cAMP lev-
els may be involved in the proximal tubular bicarbon-
ate reabsorption stimulated by angiotensin II [50, 51].
Studies in rabbit proximal tubular cells also confirmed
that physiologic concentrations of angiotensin II stim-
ulated amiloride-sensitive apical Na+/H+ antiporter ac-
tivity [52]. Angiotensin II inhibited adenyl cyclase in
renal cortical homogenates [53] and in cultured re-
nal proximal tubular cells [54]. These studies suggested
that angiotensin II stimulated the Na+/H+ antiporter
by inhibition of adenyl cyclase, possibly through an in-
hibitory G protein. Schelling et al [55] showed that an-
giotensin II–stimulated sodium transport in proximal
tubule was transduced by phospholipase C. These in-
vestigators showed that while angiotensin II inhibited
adenyl cyclase, the effect of the latter on angiotensin
II–mediated Na+ transport was mediated by phospho-
lipase C. Houillier et al [56] had shown that in intact
proximal tubule cells, angiotensin II stimulated the apical
Na+/H+ antiport through a G protein–dependent protein
kinase C pathway, whereas at higher dose, angiotensin II
inhibited Na+/H+ antiport activity through cytochrome
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P-450–dependent metabolites. However, Cano et al [57]
demonstrated that in OKP cells, angiotensin II increased
Na+/H+ antiporter activity without affecting the cAMP
production. Furthermore, the angiotensin II modulation
of Na+/H+ antiporter activity may be dependent on the
subtype of angiotensin II receptor [58]. In opossum kid-
ney cells (OK-RR cells), for example, angiotensin inhi-
bition by Dup 753, an AT1 receptor blocker, abolished
angiotensin II stimulation of Na+/H+ activity but not
when PD123319, an AT2 receptor blocker, was used.
Thus, current evidence indicates that angiotensin II stim-
ulates H+ secretion by augmenting Na+/H+ activity ei-
ther through cAMP-dependent or cAMP-independent
pathways, although such effect may depend on the spe-
cific angiotensin II receptor subtype.
The nonreceptor tyrosine kinase, c-Src, plays a key role
in the regulation of NHE-3 by acidosis in the proximal
tubule and in mediating the effects of angiotensin II in
the vascular smooth muscle cells. Tsuganezawa, Preisig,
and Alpern [59] examined the role of c-Src in mediating
the effects of angiotensin II–induced NHE-3 activation
in cultured OKP cells. These studies confirmed that c-Src
is required for the activation of NHE-3 by angiotensin
II and thus plays an important role in mediating the ef-
fects of acidosis on Na+/H+ antiporter activity through
angiotensin II. The effects of angiotensin II on NHE-3
may be biphasic and dose dependent [60].
The effects of angiotensin II on HCO3− transport in
the loop of Henle are controversial. Studies by Good,
George, and Wang [61] have demonstrated that an-
giotensin II inhibited HCO3− absorption in isolated
perfused rat mTALH through a cytochrome P-450–
dependent mechanism. However, more recent studies by
Kwon et al [62] have demonstrated that NHE-3 may
mediate enhanced HCO3− reabsorption in the mTAL
in response to angiotensin II. In the collecting duct, in-
tercalated cells secrete H+ through increased expres-
sion of H+-ATPase in the apical membrane in response
to metabolic acidosis and thereby participate in acid-
base homeostasis. Micropuncture studies showed that an-
giotensin II modulates renal net acid secretion in the
distal tubule [63]. Recently Wall et al [64] have demon-
strated that despite dramatic up-regulation of H+ se-
cretion in the distal tubule, angiotensin II infusion did
not produce metabolic alkalosis. Compensatory reduc-
tion of H+ secretion in other nephronal segments such
as mTAL and cortical collecting duct was suggested as a
possible explanation, since angiotensin II was shown to
increase HCO3− secretion in the rabbit cortical collecting
duct [65]. Wall et al [64] showed that the angiotensin II–
induced reduction in JtCO2 in outer medullary collecting
duct (OMCD) in vitro was blocked by AT1 blocker can-
desartan, indicating that such an effect is mediated by
AT1 receptors. These data strongly support the role of
angiotensin in acid-base homeostasis.
EFFECT OF pHe ON ANGIOTENSIN II
Acidosis stimulates renal ammonia production and se-
cretion in the proximal tubule. Angiotensin II has been
shown to stimulate renal ammoniagenesis in the proximal
tubule. Studies by Nagami [66] examined the hypothesis
that the effects of acidosis on ammonia production in the
proximal tubule might be mediated through angiotensin
II. Short-term infusion (18 hours) of ammonium chloride
was used to induce metabolic acidosis in vivo mice and lu-
minal ammonia secretion was measured in S2 segments of
proximal tubules microperfused in vitro. Higher rates of
ammonia secretion were demonstrated in S2 tubules from
NH4Cl-treated mice compared to control mice. How-
ever, the enhanced ammonia secretion was abolished
when the animals received losartan, an angiotensin recep-
tor blocker, along with NH4Cl. Furthermore, addition of
angiotensin II to the microperfusion solution enhanced
the ammonia secretion in NH4Cl-treated mice. The au-
thor concluded that a short-term acid challenge induced
an adaptive increase in ammonia secretion by proximal
tubule and that angiotensin II played an important role
in the adaptive renal ammoniagenesis as a result of acute
acidosis. On the other hand, studies in neonates suggested
that the stimulation of renin-angiotensin axis by acute
metabolic acidosis is negligible [67].
Angiotensin was also shown to mediate some of the
renal effects of respiratory acidosis. The antinatriuretic
response seen in acute hypercapnic acidosis could be
blocked by angiotensin antagonists, suggesting the acti-
vation of renin-angiotensin system in response to acute
hypercapnic acidosis [68]. Acute hypercapnic acidosis
and hypoxemia causes vasoconstriction, possibly medi-
ated by angiotensin II, stimulated by acidosis. However,
studies that examined this hypothesis have not yielded
consistent results. Studies in conscious dogs [69] sub-
jected to combined acute hypoxemia and hypercapnic
acidosis showed that angiotensin might not play a role in
the initial renal vasoconstriction. However, angiotensin
II attenuated the spontaneous recovery of renal hemo-
dynamic variables to baseline as the acid-base distur-
bance continued and that vasopressin played no role in
the initial intrarenal vasoconstriction [70]. In fact alpha-
adrenoreceptors may play a more important role in me-
diating the renal vasoconstriction induced by metabolic
acidosis than angiotensin II [71]. Furthermore, combined
hypercapnic acidosis and hypoxemia act synergistically to
activate rennin-angiotensin system [72] and play a major
role in maintenance of renal hemodynamics under these
conditions.
Current evidence suggests that metabolic acidosis stim-
ulates renin-angiotensin axis and angiotensin II produc-
tion [73]. Renal responses to metabolic acidosis exhibited
in the collecting tubule may also involve mediation by an-
giotensin II. Recent studies [64] indicate that JtCO2 was
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reduced after NH4Cl ingestion in OMCD in vitro, an ef-
fect believed to be mediated by angiotensin II suggesting
that metabolic acidosis actually decreased H+ secretion
in collecting tubule, contrary to the expected compen-
satory response. The authors postulated that decreased
H+ secretion might augment K+ absorption to attenuate
hyperkalemia, seen in metabolic acidosis.
In summary, angiotensin may be involved in mediating
several renal responses to both systemic metabolic and
respiratory acidosis.
PROSTAGLANDINS
Prostaglandins are metabolites of arachidonic acid
produced by the action of prostaglandin synthase or
cyclooxygenase. Prostaglandins are produced in the kid-
ney in various segments but the collecting duct ac-
counts for major fraction of renal prostaglandin synthesis.
ProstaglandinG2 (PGG2) and prostaglandin H2 (PGH2)
are in general vasoconstrictive while prostaglandin E2
(PGE2) and prostaglandin I2 (PGI2) are vasodilatory. In
addition to strong effects on vascular smooth muscle and
mesangial cells, prostaglandins also play an important
role in renin release and tubular salt and water transport.
Role of prostaglandins in renal acidification
Most of the available evidence indicates that the pre-
dominant effect of the prostaglandins on renal function
involves salt and water transport. Currently, it is unclear
if prostaglandins play any significant role in renal acidi-
fication under basal conditions. Prostaglandins inhibited
renal ammoniagenesis in the rat proximal tubule [74].
Recent reports suggest that PGE2 may stimulate organic
anion transport (OAT) in the basolateral membrane of
several models of proximal tubules, including OK cells,
isolated renal S2 rabbit proximal tubule segments and
in human renal epithelial cells expressing OAT [75]. In
vitro studies have shown that PGE2 inhibits net HCO3−
transport in the OMCD [76]. In Madin-Darby canine kid-
ney (MDCK) cells, PGE2 caused elevation of intracellu-
lar pH resulting in intracellular alkalinization by stimula-
tion of the Na+/H+ exchanger [77]. In sickle cell disease,
indomethacin, a prostaglandin inhibitor, decreased re-
nal ammoniagenesis [78]. Low urinary levels of vasodila-
tor prostaglandins have been reported in Gordon’s syn-
drome [79], incriminating renal hypoprostaglandinism as
a pathophysiologic mechanism. Gordon’s syndrome is
characterized by hypertension, hyperkalemia, and nor-
mal renal function with hyperchloremic metabolic acido-
sis. In these patients, levels of vasodilator prostaglandins
PGE2 and 6-keto-PGF1-a are generally low.
Effects of pHe on renal prostaglandins
Currently, there is very limited information about the
effects of pHe changes on the renal prostaglandin synthe-
sis. Meclofenamate enhanced the renal ammoniagenesis
induced by mild acute metabolic acidosis, which is as-
sociated with increased urinary excretion of PGE2 and
PGF2a [80]. Based on these studies, it has been suggested
that vasoactive prostaglandins may mediate renal acidifi-
cation through other hormones such as angiotensin II and
arginine vasopressin (AVP). Sahai, Goyal, and Tannen
[81] investigated the mechanism of PGF2a-mediated in-
hibition of renal ammoniagenesis and demonstrated that
under acidified conditions, PGF2a-stimulated Na+/H+
antiporter activity in porcine proximal tubular cell (LLC-
PK1) cultures. PGF2a in lower concentrations increased
cellular alpha-ketoglutarate concentration, an effect that
was lost at higher concentrations. Thus, prostaglandins,
especially PGF2a and PGE2, modulate the renal am-
moniagenesis stimulated by metabolic acidosis [82].
Tannen and Goyal [83] showed that in perfused kid-
neys, the urinary inhibitor of ammoniagenesis induced
by acute respiratory acidosis was PGF2a. Indirect studies
suggest that vasodilatory prostaglandins mediate some
of the adverse renal effects of distal renal tubular acido-
sis such as hypercalciuria, kalliuresis, and hyperrenine-
mia since indomethacin ameliorates these effects [84].
Jones et al [74] studied the effect of systemic acid-
base disturbances on prostaglandin production in rat
kidneys. Prostaglandins inhibit renal ammoniagenesis in
rats. Acute metabolic acidosis increased total ammonia
synthesis but also stimulated prostaglandin production.
In these studies, prostaglandin inhibition with meclofe-
namate stimulated renal ammoniagenesis. In rats with
mild metabolic acidosis, renal ammoniagenesis, and uri-
nary excretion of PGE2 and PGF2a were greatly in-
creased and administration of meclofenamate markedly
reduced urinary prostaglandin excretion, further aug-
mented ammonia synthesis, and significantly increased
the fractional excretion of NH3. Inhibition of stimu-
lated prostaglandin synthesis during severe metabolic
acidosis did not increase ammoniagenesis or fractional
excretion of NH3. Acute metabolic alkalosis did not al-
ter production of prostaglandins or ammonia, but re-
duced the fractional excretion of NH3. It was concluded
from these studies that prostaglandins inhibit ammo-
nia synthesis in normal rats and in those undergoing
mild metabolic acidosis. Severe acidosis overrides this
inhibitory effect of prostaglandins on ammoniagenesis,
whereas metabolic alkalosis suppresses the stimulatory
effect of prostaglandin inhibition on ammoniagenesis.
CLINICAL RELEVANCE OF INTERACTIONS
OF RENAL VASOACTIVE FACTORS AND pHe
Chronic renal failure (CRF)
Metabolic acidosis is an integral feature of many forms
of CRF. Since decreased intrarenal nitric oxide produc-
tion is known to mediate mesangial sclerosis, a criti-
cal determinant of progressive CRF, it is important to
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understand the effects of acidosis on intrarenal nitric ox-
ide production. Studies from my laboratory [31] and oth-
ers support that decreased pHe is associated with nitric
oxide inhibition. Based on these data, it is likely that in-
hibition of intrarenal nitric oxide synthesis may be much
more pronounced in those forms of CRF which are asso-
ciated with severe metabolic acidosis. Untreated acidosis
under such conditions may contribute to the progression
of CRF by amplifying the intrarenal nitric oxide inhibi-
tion that is seen in most forms of CRF. Further studies are
needed to establish the role of nitric oxide inhibition due
to acidosis in the progression of CRF and whether ame-
lioration of acidosis enhances the intrarenal nitric oxide
production and decreases the rate of progression of renal
failure. Furthermore, some evidence exists to incriminate
prostaglandins in mediating demineralization of bone, a
process that may be associated with the metabolic acido-
sis of uremia [85].
Diabetic renal disease
Diabetic nephropathy itself is associated with severe
abnormalities of nitric oxide with mechanisms operating
in parallel that both enhance and diminish the nitric ox-
ide release in the kidney [86]. Uncontrolled diabetes was
shown to increase NOS activity particularly NOS I and
NOS III and stimulate Na+/H+ exchange activity in prox-
imal tubules [87]. However, several studies indicate that
as the duration of diabetic nephropathy increases, fac-
tors that suppress bioavailability of nitric oxide such as
formation of advanced glycation end-products (AGEs)
and reactive oxygen species (ROS) prevail [88]. In addi-
tion, metabolic acidosis of renal disease may be severe
and occur early in the course of diabetic renal failure.
The problem is compounded by the frequent occurrence
of type IV renal tubular acidosis in diabetic nephropathy.
Septicemia
There is a large body of evidence supporting the role
of nitric oxide, particularly inducible nitric oxide, in the
generation of metabolic acidosis of septicemia. Copious
amounts of cytokine-mediated nitric oxide leads to va-
sodilatation and decreased tissue profusion and thereby
result in lactic acidosis. Recent studies by Kellum et al [89]
showed that moderate hyperchloremic metabolic acido-
sis (base excess −5 to −10 mEq/L) worsened hemody-
namics in a rat model of sepsis, in association with in-
creased stable metabolites of nitric oxide in plasma ni-
trites, and nitrates (NOx), while severe acidosis (base ex-
cess −10 to −15 mEq/L) also worsened hemodynamics
but without affecting the plasma nitrites and nitrates. The
authors concluded that the mechanism(s) responsible for
hypotension in this setting are unclear. However, they
are likely to be complex, and may involve increased nitric
oxide release when acidosis is moderate and other mech-
anisms when more severe. Furthermore, the effect of aci-
dosis on plasma NOx may also depend on the type of acid
involved [90]. For example, hydrochloric acid as in hy-
perchloremic metabolic acidosis increased lipopolysac-
charide (LPS)-induced NOx release from macrophages
while lactic acid, as seen in lactic acidosis, did not. Many
studies that used various inhibitors of NOS, particularly
iNOS specific blockers, resulted in amelioration of aci-
dosis in the context of septicemia [91]. However, many
detrimental effects have been reported from such NOS
inhibitors, including increase in pulmonary resistance, de-
creased cardiac output, and organ perfusion [92]. In the
context of endotoxic shock, nitric oxide released from
eNOS (NOS III), on the other hand, may have a bene-
ficial effect in protecting against the deleterious effects
of thromboxanes and leukotrienes [92]. Thus selective
iNOS blockers are preferred over nonselective inhibitors
for treatment of septic shock [93]. Studies have demon-
strated that selective iNOS blockers are better than even
adrenergic support with norepinephrine in treatment of
sepsis [94]. In patients with sepsis, treatment with ibupro-
fen, an inhibitor of vasodilatory renal prostaglandins,
reduces levels of prostacyclin and thromboxane and
decreases fever, tachycardia, oxygen consumption, and
lactic acidosis, but it does not prevent the development
of shock or the acute respiratory distress syndrome and
does not improve survival [95]. The pathogenic role of
ET in endotoxic shock is supported by the efficacy of
selective blockade of ET receptors, specifically ETB in
diminishing liver injury and failure [96].
Diabetic ketoacidosis (DKA)
While there is a rapidly growing data about abnormali-
ties of nitric oxide in diabetic state, literature about nitric
oxide alterations in DKA is limited. Iori et al [97] re-
ported increased levels of nitrate and iNOS mRNA and
protein in lymphomonocytes in DKA. These changes are
believed to mediate vascular abnormalities in DKA, such
as increase in precapillary vasodilation. But correction
of ketosis only partially decreased the changes in nitric
oxide abnormalities and iNOS expression. The authors
ascribed the persistence of nitric oxide abnormalities to
large amounts of insulin required to correct ketosis. Uri-
nary excretion of prostaglandins has been reported to
be abnormal in patients with diabetic ketoacidosis [98].
Specifically vasodilatory prostaglandins such as PGE2a
and its metabolites as well as PGI2, were increased in
urine of patients with DKA. It was suggested that such
changes may be protective and counter balance the vaso-
constrictor processes associated with DKA.
Renal tubular acidosis
Knockout mice deficient in nNOS exhibit a metabolic
acidosis [11], clearly indicating an important role for
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nitric oxide in the transport of H+/HCO3− in the kidney.
Modulation of renal tubular acidosis (RTA) by nitric ox-
ide has been recently described by Tsuruoka et al [99]
in a rat model of cyclosporine A (CyA) toxicity. Indeed,
CyA has been found to inhibit nitric oxide production
in a variety of cell types [100]. Inhibition of nitric oxide
synthesis may be one of the mechanisms underlying the
CyA effect. Tsuruoka et al [99] demonstrated that admin-
istration of L-NAME, a NOS inhibitor, exacerbated and
L-arginine ameliorated the impaired HCO3 reabsorption
seen with acid challenged CyA-treated rats. Using mod-
els of perfused cortical collecting duct, it was concluded
that CyA causes distal RTA by inhibiting H+ pumps in
the distal nephron.
CONCLUSION
It is apparent from the preceding discussion that
changes in systemic acid-base status regulate the gen-
eration of vasoactive cytokines in the kidney and these
factors, in turn, may play a role in the adaptive renal
responses to the initiating alteration in the H+ concen-
tration in the tissues. Furthermore, the data presented
strongly support the concept that these factors, particu-
larly ET and nitric oxide, play an important role in the
normal H+ homeostasis by regulating renal acidification
mechanisms. In general, the currently available informa-
tion suggests an inverse relationship between nitric oxide
and ET, with reference to their effects on renal acidifica-
tion mechanisms as well as pHe effects on these factors.
Thus, reduced pHe inhibits nitric oxide while stimulat-
ing ETs and possibly even angiotensin II in the kidney.
Further studies need to be conducted to enhance the cur-
rent understanding of the interactions of angiotensin II
and prostaglandins with renal acidification mechanisms
in health and disease. Such studies are necessary to un-
ravel the complex interactions between the H+ concen-
tration and the vasoactive cytokines and to expand our
knowledge of regulatory controls involved in the home-
ostatic mechanisms in conditions of health and systemic
acid-base disorders.
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